SAN FRANCISCO--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. today announced the first patient has been enrolled in a Phase I clinical trial of its investigational protein therapeutic, FP-1039, in patients with advanced solid tumors. FP-1039 is an FGFR1:Fc fusion protein shown in pre-clinical studies to inhibit angiogenesis and slow the growth of tumors.
